Trichinella nativa is one of the several species of Trichinella, a genus of parasitic roundworms that can infect humans and animals. The primary mode of transmission of Trichinella is through the consumption of raw or undercooked meat containing the infective larvae. Trichinella nativa is primarily found in the Arctic and subarctic regions and is commonly associated with the consumption of wild game meat, such as bear or walrus.

The pathogenesis of Trichinella infection is complex and involves a variety of mechanisms, including the release of excretory-secretory (ES) proteins by the parasite. These proteins play a critical role in the host-parasite interaction and can modulate the host immune response to facilitate the establishment and persistence of infection.

Two notable ES proteins of Trichinella nativa are the 49 kDa E-S protein and the 53 kDa excretory-secretory protein. The 49 kDa E-S protein has been identified as a highly immunogenic protein that is recognized by host antibodies during infection. Studies have shown that this protein can modulate the host immune response and facilitate the establishment of infection.

The 53 kDa excretory-secretory protein, on the other hand, has been identified as a potential diagnostic marker for Trichinella infection. Studies have shown that this protein is highly specific and sensitive for the detection of Trichinella infection in humans and animals.

Targeting Trichinella’s ES proteins, such as the 49 kDa E-S protein and the 53 kDa excretory-secretory protein, may hold promise for the development of novel diagnostic and therapeutic interventions for Trichinella infection. Furthermore, a deeper understanding of the pathogenesis of Trichinella infection and the role of ES proteins in this process may aid in the development of effective control measures for this parasitic disease.

Trichinella nativa cDNA and recombinant antigens are used in a variety of different applications. These include:
1. Diagnostic tests: cDNA and recombinant antigens derived from Trichinella nativa can be used to detect the presence of the parasite in clinical samples. Detection can be done by PCR or ELISA.
2. Vaccine development: cDNA and recombinant antigens derived from Trichinella nativa can be used in the development of vaccines to protect against the parasite.
3. Research: cDNA and recombinant antigens derived from Trichinella nativa can be used in research to study the structure, function, and behavior of the parasite. This can be done to gain insights into its biology and develop new treatments.
4. Drug development: cDNA and recombinant antigens derived from Trichinella nativa can be used in developing new drugs to treat the infection.
5. Serological studies: cDNA and recombinant antigens derived from Trichinella nativa can be used to study the serological responses to the parasite in different populations.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.